24 April 2015
As of 2014, Teva ($TEVA) is in the No. 11 spot on the list of pharma's top revenue generators. But if it gets its way and lands a deal for rival generics maker Mylan ($MYL), just how much will it be moving up the charts?
A combined company would boast pro forma 2014 revenues tallying about $30 billion, the Israeli drugmaker said Tuesday with the announcement of its $40 billion bid. And that would land it solidly in the No. 8 spot, between British giants GlaxoSmithKline ($GSK)--which generated $37.96 billion last year--and AstraZeneca ($AZN), which hauled in $26.095 billion.
As a result, AstraZeneca would slide into the No. 9 slot, Bayer HealthCare into the No. 10 space, and current No. 10--Gilead Sciences ($GILD), vaulted recently by standout launches for its hep C stars Sovaldi and Harvoni--would have to kiss the top 10 goodbye. Of course, all of that could change in 2015; Gilead, with $24.47 billion last year, didn't come in far behind Bayer, which racked up $25.47 billion.
egardless, it would be quite the jump for Teva, which posted $20.27 billion in 2014--much of it on the back of lead product Copaxone, which as of last week has an FDA-approved knockoff in Sandoz and Momenta's ($MNTA) Glatopa. But it's one the company is eager to take. Combining Teva and Mylan "would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry," CEO Erez Vigodman in a statement.
It's not the first time lately that pharma has seen its revenue ranks shaken up by a transaction. Thanks to a major M&A year last year--the largest in recent memory--the order could see some shuffling. After all, Bayer's not far behind AstraZeneca, and it last October sealed a deal for a Merck ($MRK) consumer health unit that churned out $2.2 billion in 2013 sales.
Additionally, newly beefed up Actavis ($ACT)--which as of March has folded in Allergan--predicts $23 billion in sales this year, and if that forecast holds up, it could take the spot behind Gilead--No. 12 if Teva makes its jump, and No. 11 if it doesn't.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024